Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy

Cancer Gene Therapy

Volumn 13, Issue 8, 2006, Pages 771-779

  Gunther M ^a   Waxman, D J ^b   Wagner, E ^a   Ogris, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Boston University   (United States)

Author keywords

Agarose overlay; Cyclophosphamide; Cytochrome P450; GDEPT

Indexed keywords

AGAROSE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; IFOSFAMIDE; PRODRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CELL POPULATION; CONTROLLED STUDY; DIFFUSION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; GENE THERAPY; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; METABOLITE; MICROENVIRONMENT; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR CELL; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BYSTANDER EFFECT; CELL CULTURE TECHNIQUES; CELL DEATH; CELL HYPOXIA; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; DIFFUSION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; HUMANS; MICE; PLASMIDS; PRODRUGS; SEPHAROSE; TRANSFECTION; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 33746266759     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700955     Document Type: Article

References (25)

1. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-359.
2. Gunther M, Wagner E, Ogris M. Specific targets in tumor tissue for the delivery of therapeutic genes. Curr Med Chem Anti-cancer Agents 2005; 5: 157-171.
3. Roy P, Waxman DJ. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol in Vitro 2006; 20: 176-186.
4. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995; 1: 1171-1177.
5. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581-589.
6. Jounaidi Y, Waxman DJ. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 2004; 64: 292-303.
7. Wright JE, Tretyakov O, Ayash LJ, Elias A, Rosowsky A, Frei III E. Analysis of 4-hydroxycyclophosphamide in human blood. Anal Biochem 1995; 224: 154-158.
8. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003; 66: 1207-1218.
9. 2 and pH semi-microelectrodes. Eur J Cancer 1992; 29A: 116-122.
10. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999; 1: 197-207.
11. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 2000; 60: 3761-3769.
12. Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 2005; 11: 1512-1520.
13. Boeckle S, von Gersdorff K, van der PS, Culmsee C, Wagner E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med 2004; 6: 1102-1111.
14. Donato MT, Gomez-Lechon MJ, Castell JV. A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 1993; 213: 29-33.
15. Kim MH, Jung YS, Moon CH, Lee SH, Baik EJ, Moon CK. High-glucose induced protective effect against hypoxic injury is associated with maintenance of mitochondrial membrane potential. Jpn J Physiol 2003; 53: 451-459.
16. von Gersdorff K, Ogris M, Wagner E. Cryoconserved shielded and EGF receptor targeted DNA polyplexes: cellular mechanisms. Eur J Pharm Biopharm 2005; 60: 279-285.
17. Rao J, Otto WR. Fluorimetric DNA assay for cell growth estimation. Anal Biochem 1992; 207: 186-192.
18. Yuan F, Krol A, Tong S. Available space and extracellular transport of macromolecules: effects of pore size and connectedness. Ann Biomed Eng 2001; 29: 1150-1158.
19. Ding Q, Kestell P, Baguley BC, Palmer BD, Paxton JW, Muller G et al. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmacol 2002; 50: 186-192.
20. Sladek NE. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazophosphorines. In: Powis G (ed). Anticancer Drugs: Reactive Metabolism and Drug Interactions. Pergamon Press Ltd: Oxford, 1994, pp 79-156.
21. Chen L, Waxman DJ. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des 2002; 8: 1405-1416.
22. Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol 2003; 2003: 48-70.
23. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 2000; 60: 3761-3769.
24. Yuan F, Krol A, Tong S. Available space and extracellular transport of macromolecules: effects of pore size and connectedness. Ann Biomed Eng 2001; 29: 1150-1158.
25. Ding Q, Kestell P, Baguley BC, Palmer BD, Paxton JW, Muller G et al. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmacol 2002; 50: 186-192.